Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

April 9, 2024

https://www.globenewswire.com/news-release/2024/04/09/2859912/0/en/Tempest-Reports-New-Preclinical-Data-for-TPST-1120-in-RCC-at-the-AACR-Annual-Meeting.html

BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating that TPST-1120 reduces kidney cancer (RCC) growth as a monotherapy, while also showing increased inhibition when combined with frontline chemotherapy and immunotherapy. These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.